Dainippon Sumitomo Pharma Advances Pipeline Despite Setbacks
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Osaka-based Dainippon Sumitomo scored a few advances in its pipeline despite an earlier setback for its epilepsy medicine Stedesa (eslicarbazepine) when U.S. FDA asked for additional information last November and extended its PDUFA date 90 days to April 30, the company reported Feb. 3 when it announced earnings results for the April-December period. Stedesa is being developed by Dainippon's new subsidiary Sepracor